NIKKEI 225
38,218.92 -55.13 (-0.14%) HANG SENG
18,183.63 +420.60 (+2.37%) CRUDE OIL
79.52 +0.52 (+0.66%) GOLD FUTURES
2,323.70 +12.70 (+0.55%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,857.41 -1,903.54 (-3.99%)
MannKind Corporation (MNKD)
After hours:
| Previous close | 4.1100 |
| Open | 4.1900 |
| Bid | 4.3100 x 1100 |
| Ask | 4.3400 x 1200 |
| Day's range | 4.1500 - 4.3925 |
| 52-week range | 3.1700 - 5.7500 |
| Volume | |
| Avg. volume | 2,934,175 |
| Market cap | 1.175B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.08 |
GlobeNewswireMannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentat
- GlobeNewswire
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteersEnrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will proceed with a first-i
- GlobeNewswire
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Ph
